Search Within

Michael Andrew Postow

Formats
  1. Journal Article (196)
  2. Meeting Abstract (138)
  3. Review (10)
  4. Editorial (9)
  5. Book Section (4)
  6. Guidelines (4)
  7. Research Letter (4)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Correspondence (1)
Groups
  1. Department of Medicine (369)
  2. Melanoma Disease Management Team (369)
  3. Melanoma and Immunotherapeutics Service (369)
  4. Solid Tumor Oncology Division (369)
  5. GSK Faculty (178)
  6. Hematologic Malignancies, Division of (105)

More Groups

People
  1. Jedd Wolchok (158)
  2. Margaret Callahan (96)
  3. Katherine Panageas (66)
  4. Alexander Shoushtari (64)
  5. Paul Chapman (55)
  6. Parisa Momtaz (37)

More People

Years
  1. 2025 (23)
  2. 2024 (19)
  3. 2023 (23)
  4. 2022 (23)
  5. 2021 (27)
  6. 2020 (30)

More Years

Publications
  1. Journal of Clinical Oncology (92)
  2. Journal for ImmunoTherapy of Cancer (34)
  3. Clinical Cancer Research (16)
  4. Annals of Oncology (13)
  5. International Journal of Radiation Oncology, Biology, Physics (12)
  6. The Oncologist (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. Biomed Central Ltd (43)
  3. Elsevier Inc. (32)
  4. Oxford University Press (32)
  5. American Association for Cancer Research (24)
  6. Wiley Blackwell (21)

More Publishers

Results (369)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiotherapy and immune checkpoint blockade for melanoma: A promising combinatorial strategy in need of further investigation
    Journal Article

    Escorcia, F. E.; Postow, M. A.; Barker, C. A.
    The Cancer Journal (2017)

    Fulltext@MSK | Save
  • Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma
    Journal Article

    Shoushtari, A. N.; Bluth, M. J.; Goldman, D. A.; Bitas, C.; Lefkowitz, R. A.; Postow, M. A.; Munhoz, R. R.; Buchar, G.; Hester, R. H.; Romero, J. A.; more...
    Melanoma Research (2017)

    Fulltext@MSK | Save
  • Reaffirming and clarifying the American Society of Clinical Oncology's policy statement on the critical role of phase I trials in cancer research and treatment
    Journal Article

    Weber, J. S.; Levit, L. A.; Adamson, P. C.; Bruinooge, S. S.; Burris, H. A. 3rd; Carducci, M. A.; Dicker, A. P.; Gönen, M.; Keefe, S. M.; Postow, M. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM)
    Meeting Abstract

    Tsai, K. K.; Shoushtari, A. N.; Munhoz, R. R.; Eroglu, Z.; Piulats, J. M.; Ott, P. A.; Johnson, D. B.; Hwang, J.; Daud, A.; Sosman, J. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)
    Meeting Abstract

    Shoushtari, A. N.; Navid-Azarbaijani, P.; Friedman, C. F.; Panageas, K.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Campbell, S. C.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone
    Meeting Abstract

    Postow, M. A.; Kuk, D.; Adamow, M.; Carrera, C.; Wong, P.; Curran, M. A.; Friedman, C. F.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical activity of anti -programmed death-1 (PD-1) agents in acral and mucosal melanoma
    Meeting Abstract

    Munhoz, R. R.; Shoushtari, A. N.; Kuk, D.; Ott, P. A.; Johnson, D. B.; Tsai, K. K.; Rapisuwon, S.; Eroglu, Z.; Sullivan, R. J.; Luke, J. J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069)
    Meeting Abstract

    Hodi, F. S.; Postow, M. A.; Chesney, J. A.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)
    Meeting Abstract

    Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)
    Meeting Abstract

    Friedman, C. F.; Horvat, T. Z.; Minehart, J.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save